FDA 483 OBSERVATION · #720 OF 1,932 MOST-CITED

Consent not obtained, exceptions do not apply

FDA cited this observation 29 times across 29 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

What this grouping is not

An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.

BY PROGRAM AREA
Bioresearch Monitoring29
BY FISCAL YEAR
FY20265
FY20251
FY20242
FY20232
FY20221
FY20213
FY20201
FY20194
FY20184
FY20172
FY20164

How FDA worded it — real examples

Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.

Aarti K. Bhatia, MD, MPH · New Haven, Connecticut · Bioresearch Monitoring · 2026-08-07

Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.

Blake G. Simmons, OD · Colorado Springs, Colorado · Bioresearch Monitoring · 2026-07-27

Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.

Jeffrey J. Sperinde, PhD · South San Francisco, California · Bioresearch Monitoring · 2026-06-30

Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.

Breelyn A Wilky MD · Aurora, Colorado · Bioresearch Monitoring · 2026-06-25

Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.

Javier Sosa Faria, M.D. · Ponce, Puerto Rico · Bioresearch Monitoring · 2025-10-31

Legally effective informed consent was not obtained from a subject or the subject's legally authorized representative, and the situation did not meet the criteria in 21 CFR 50.23 - 50.24 for exception.

Mark Dacey, M.D. · Denver, Colorado · Bioresearch Monitoring · 2024-11-08

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

GCP discipline →

Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →